Company profile · Dessau-Rosslau, Germany

IDT Biologika

Viral Vaccines, Cell and Gene Therapy, and Fill-Finish CDMO · Commercial biologics CDMO

Verified 14 Mar 2026 · 3 sources

CDMOBiologicsGene TherapyVaccineFill-finishCommercial
GermanyCDMODessau-Rosslau

Commercial vaccine and biologics campus combining aseptic fill-finish, cold-chain release, and multi-suite GMP manufacturing for international programs.

Lead
Dr. Sally Choe (verified ↗)
Compliance
GMP Manufacturing · FDA / EMA / ANVISA Quality Standards
Last reviewed
14 Mar 2026 (5mo ago)
Scale
Commercial biologics CDMO
Capabilities
Viral Vaccine Manufacturing · Cell and Gene Therapy Services · Aseptic Fill-Finish
Founded
1921
Headcount
1001-5000
Editorial note

Viral Vaccines, Cell and Gene Therapy, and Fill-Finish CDMO

Commercial vaccine and biologics campus combining aseptic fill-finish, cold-chain release, and multi-suite GMP manufacturing for international programs.

Editorial note

The current management layer remains dual-lead; the registry keys Dr. Sally Choe as the verified executive anchor for this record.

Current review cycleMarch 2026Last reviewed: 14 March 2026

Verification details

Site and address
Clinical profileSTATUS: VERIFIED MARCH 2026

Dr. Sally Choe

Co-CEO

Check official leadership source
Full addressAm Pharmapark, 06861 Dessau-Rosslau, Germany
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source

Official IDT Biologika contact page naming the Dessau-Rosslau site at Am Pharmapark.

Open source
Operating profile

Commercial biologics CDMO

Dessau-Rosslau, Germany. Viral Vaccines, Cell and Gene Therapy, and Fill-Finish CDMO. Review completed on 14 Mar 2026.

2026 technical specializationViral Vaccines, Cell and Gene Therapy, and Fill-Finish CDMO
Core capabilities
Viral Vaccine ManufacturingCell and Gene Therapy ServicesAseptic Fill-Finish
Governance

Paul-Ehrlich-Institut (PEI)

GMP Manufacturing, Biologics Fill-Finish, FDA / EMA / ANVISA Quality Standards

Capabilities

Viral Vaccine Manufacturing
Cell and Gene Therapy Services
Aseptic Fill-Finish

Sources

The official sources used to verify this profile.

Leadership evidenceIDT Biologika management page.Source origin: idt-biologika.comOpen source
Supporting evidenceIDT Biologika influenza consortium release naming Dr. Sally Choe as Co-CEO.Source origin: idt-biologika.comOpen source
Physical-site evidenceOfficial IDT Biologika contact page naming the Dessau-Rosslau site at Am Pharmapark.Source origin: idt-biologika.comOpen source

Infrastructure

Vaccine process suites
Aseptic filling lines
Cold-chain release laboratories

Certifications

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
VERIFIED ACTIVE 2026
GLP
REVIEW IN PROGRESS 2026
ISO-13485
REVIEW IN PROGRESS 2026
FDA-Inspected
REVIEW IN PROGRESS 2026

Review log

14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: All seven review areas are complete.

Frequently asked questions

Where is IDT Biologika located?
IDT Biologika operates from Am Pharmapark, 06861 Dessau-Rosslau, Germany, Dessau-Rosslau, Germany.
Who runs IDT Biologika?
IDT Biologika is led by Dr. Sally Choe, Co-CEO. Verified 14 Mar 2026.
What certifications does IDT Biologika hold?
IDT Biologika is documented under GMP Manufacturing, FDA / EMA / ANVISA Quality Standards.
What does IDT Biologika do?
Commercial vaccine and biologics campus combining aseptic fill-finish, cold-chain release, and multi-suite GMP manufacturing for international programs. Core capabilities: Viral Vaccine Manufacturing, Cell and Gene Therapy Services, Aseptic Fill-Finish.
Editorial context

Related technical briefs

Briefs that name Dessau-Rosslau as a covered market or city.